Galiano Ventures

Galiano Bio is a clinical-stage biotechnology company dedicated to developing gene therapies for rare, fatal lysosomal storage diseases. The company's primary focus is on GM1 and GM2 gangliosidosis, neurodegenerative disorders caused by mutations in genes responsible for breaking down lipids in the brain. Galiano Bio utilizes an adeno-associated virus (AAV) platform to deliver functional genetic material directly to the central nervous system. Its lead candidate, GB-101, is currently being evaluated in clinical trials for the treatment of GM1 gangliosidosis. Founded and backed by Deerfield Management, the company is headquartered in New York City and leverages the firm's extensive resources in drug development and rare disease research.